



*Small, but heading for the big time*

## ***Nanobiotix revenue for the 2<sup>nd</sup> quarter of 2014***

**Paris, France, July 11, 2014** – **NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205)**, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2014.

### **Income statement**

<i>In €</i>	<i>Q2 2014</i>	<i>H1 2014</i>	<i>Q2 2013</i>
<b>Revenues</b>	<b>48,596</b>	<b>93,939</b>	<b>48,569</b>
Of which :			
<i>License</i>	45,847	91,190	45,847
<i>Services</i>	2,749	2,749	2,722

### **Activity**

The revenue recorded by NANOBOTIX during the second quarter of 2014 relates to the upfront payment (pro-rata share) from the Taiwan-based PharmaEngine within the framework of the licensing contract. This licensing contract was signed in August 2012 for the development and commercialization of Nanobiotix's lead product, NBTXR3 in the Asia-Pacific region. It is distributed using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region. This upfront payment totaled €810,640, generating a product of €45,847 for the period and totalling €91,190 for the first semester in 2014. The invoicing of services totalled €2,749 for the second quarter of 2014. In total, revenue for the second quarter amounts €48,596. Revenue for the first half of 2014 is €93,939 which is fully in line with Company expectations.

During Q2, Nanobiotix presented successful Phase I results for its lead product NBTXR3 at the American Society of Clinical Oncology (ASCO). Final results demonstrated very good safety, treatment feasibility and promising signs of efficacy in patients with advanced Soft Tissue Sarcomas. These results allow Nanobiotix to proceed to the pivotal phase, which is the final step leading to registration (CE mark), and is planned to commence in Q4 2014.

***Next financial press release: results for the first half of 2014 to be released on August 29, 2014***

•••

**About NANOBOTIX:** [www.nanobiotix.com/fr](http://www.nanobiotix.com/fr)

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

**Contacts**

---

**Nanobiotix**

**Sarah Gaubert**  
*Head of Communication and Public Affairs*  
+33 (0)1 40 26 07 55  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

---

*Financial communication and investors relations*

**NewCap**  
**Emmanuel Huynh / Louis-Victor Delouvrier**  
+33 (0)1 44 71 98 53  
[lydelouvrier@newcap.fr](mailto:lydelouvrier@newcap.fr)



---

*Media relations*

France - **NewCap**  
**Annie-Florence Loyer**  
+33 (0) 1 44 71 94 93  
[afloyer@newcap.fr](mailto:afloyer@newcap.fr)

Outside France - **Instinctif Partners**  
**Melanie Toyne Sewell**  
+44 (0) 207 457 2020  
[nanobiotix@instinctif.com](mailto:nanobiotix@instinctif.com)